[Immunopoiesis- and erythropoiesis-modulating properties of trecresan in experimental immune deficiency].
The effect of trecrezan, a new immunoactive biostimulator, was studied in (C57BL/6 x DBA/2)F1 mice with immunodeficiency and anemia syndromes induced by a chronic guest-versus-host reaction. The drug combines immuno- and erythromodulant properties, being capable of eliminating anemia, decreasing the number of erythrokaryocytes and BFUs in bonemarrow of ill mice, and normalizing primary humoral immune response. Possible mechanisms of trecrezan action are discussed.
Sukhenko
T G
TG
Institute of Clinical Immunology, Siberian Division, Russian Academy of Medical Sciences, ul. Yadrintsevskaya, 14, Novosibirsk, 630099 Russia.
Kolesnikova
O P
OP
Kozlov
V A
VA
D000085:Acetates / Q000627:therapeutic use*; D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000740:Anemia / Q000097:blood / Q000150:complications / Q000276:immunology; D000818:Animals; D000921:Antibody-Producing Cells; D001854:Bone Marrow Cells; D004338:Drug Combinations; D004920:Erythropoiesis / Q000187:drug effects*; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006789:Host vs Graft Reaction; D007153:Immunologic Deficiency Syndromes / Q000097:blood / Q000150:complications / Q000276:immunology*; D007375:Interleukin-1 / Q000096:biosynthesis; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA
D000085:Acetates; D000276:Adjuvants, Immunologic; D004338:Drug Combinations; D004983:Ethanolamines; D007375:Interleukin-1; C047413:crezacin